Neurology

Sage Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Pipeline and Business Progress

Retrieved on: 
Tuesday, August 2, 2022
Mental Health, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Zuranolone, GABAA receptor positive allosteric modulator, Company, Incidence, File, Safety, Lists of diseases, Disorder, Review, Grammatical mood, Security (finance), NEST, Spectrum, Goal, Insomnia, Research, U.S. Securities and Exchange Commission, Neuropsychiatry, CIV, Solution, Government budget balance, PAM, Tremor, Depression, D, Program, Growth, IND, Clinical research associate, PPD, NMDA, Food, REM, Binary relation, GABA, Risk, Webcast, Achievement, Epilepsy, FDA, Particle-size distribution, Nasdaq, Neurology, Sleep, Essential tremor, GABAA, Plasma, Time, SG, PD, Private Securities Litigation Reform Act, NDA, Rehabilitation, Therapy, MDD, Patient, MCI, Fine chemical, Pharmaceutical industry, Risk management, Beauty salon, Boilermaker, Tutoring, Sage, Biogen, HD

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the second quarter ended June 30, 2022.

Key Points: 
  • Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the second quarter ended June 30, 2022.
  • In the second quarter of this year, Sage and its collaborator, Biogen, announced that the SKYLARK Study of zuranolone in PPD met its primary and all key secondary endpoints.
  • Net Loss: Net loss was $126.3 million for the second quarter of 2022 compared to $107.2 million for the same period of 2021.
  • ET to discuss its second quarter 2022 financial results and recent corporate updates.

Phillip A. Villanueva, MD, ABNS, is being recognized by Continental Who's Who

Retrieved on: 
Tuesday, August 2, 2022
Association, ABNS, Chemistry, University, Awareness, Temple University Hospital, Brain, Neuroscience, Critical care, St. Thomas University (Florida), American Association of Neurological Surgeons, Neurology, American Association, Continental, Multimedia, General surgery, Neuro, Philosophy, Certification, Mentorship, Temple University, Theology, Congress of Neurological Surgeons, St. Thomas University, Biology, Medical degree, American Board of Commissioners for Foreign Missions, Dentistry, Medicine, Neurosurgery, MD, Science

A highly trained neurosurgeon with 47 years of experience in his field, Dr. Villanueva specializes in surgeries for brain injuries and neuro-critical care.

Key Points: 
  • A highly trained neurosurgeon with 47 years of experience in his field, Dr. Villanueva specializes in surgeries for brain injuries and neuro-critical care.
  • For the past eight years, he has served as the Director of Neuro Trauma and Critical Care at Temple University Hospital in Philadelphia, PA.
  • He additionally serves as a Professor of Clinical Neurosurgery at the Lewis Katz School of Medicine at Temple University.
  • Dr. Villanueva is a member of the American Association of Neurological Surgeons, where he sits on the subcommittee for neuro-critical care.

Sosei Heptares and AbbVie Enter New Multi-target Collaboration to Discover, Develop and Commercialize Novel Medicines Targeting Neurological Diseases

Retrieved on: 
Tuesday, August 2, 2022
Novartis, Inflammation, GLOBE, GPCR, Invention, NYSE, Research, ABBV, Intention, Gastroenterology, Failure, Lists of diseases, Takeda, AbbVie, GSK, Technology, Investigational New Drug, Tokyo Stock Exchange, AstraZeneca, Neurology, Neurocrine Biosciences, IND, Pharmaceutical industry, Fine chemical, Genentech, Pfizer

The new agreement will leverage Sosei Heptares StaR technology and structure-based drug design (SBDD) platform and AbbVies extensive neuroscience and disease area expertise.

Key Points: 
  • The new agreement will leverage Sosei Heptares StaR technology and structure-based drug design (SBDD) platform and AbbVies extensive neuroscience and disease area expertise.
  • Under the terms of the new agreement, Sosei Heptares will conduct and fund R&D activities through the completion of Investigational New Drug (IND)-enabling studies.
  • We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including neurology, immunology, gastroenterology and inflammatory diseases.
  • Sosei Heptares is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565).

Quanterix’ Second Quarter 2022 Earnings Conference Call

Retrieved on: 
Monday, August 1, 2022
Health, Technology, Other Technology, Other Health, Research, Science, Corporation, U.S. Securities and Exchange Commission, Forward-looking statement, Research, Risk, Private Securities Litigation Reform Act, Infection, NASDAQ, News, Webcast, Quality of life, Inflammation, Technology, Science, Cardiology, Baozou Big News Events, Neurology, Longevity, Investor, Population

Quanterix Corporation (NASDAQ: QTRX), a company expanding the limits of exploration with ultrasensitive biomarker detection, today announced it will host a conference call on Monday, August 8, 2022, to discuss its second quarter 2022 financial results.

Key Points: 
  • Quanterix Corporation (NASDAQ: QTRX), a company expanding the limits of exploration with ultrasensitive biomarker detection, today announced it will host a conference call on Monday, August 8, 2022, to discuss its second quarter 2022 financial results.
  • Quanterix will issue a press release regarding the second quarter 2022 earnings prior to the conference call.
  • Please click here to pre-register for the conference call and obtain your dial in number and passcode.
  • Forward-looking statements in this news release are based on Quanterix expectations and assumptions as of the date of this press release.

Novogene America Launches a New Single-Cell Lab in San Jose. CA, Based on Chromium Platform Powered by 10x Genomics®

Retrieved on: 
Monday, August 1, 2022
Silicon, Gene expression, SCI, 10x Genomics, NGS, SAN, Research, Biomarker, B cell, Solution, Nature, Lab, Cell, Next, Publication, NovoGen, Genomics, Biology, Neurology, Gel, RNA-Seq, GEM, RNA, UMI, Vaccine, Science, Illumina

Now, Novogene America launches a new lab in USA specifically offering 10x scRNA-seq services for respectable clients.

Key Points: 
  • Now, Novogene America launches a new lab in USA specifically offering 10x scRNA-seq services for respectable clients.
  • Novogene America 10x scRNA-Seq lab is located in San Jose, California, United States.
  • The Lab features the Next GEM Technology, Chromium Controller platform, which is an uplifting milestone for becoming a fully independent vendor for 10x scRNA-seq services.
  • With the new coming lab, Novogene launches more gene solutions related to the single cell sequencing.

ALZHEIMER'S ASSOCIATION LAUNCHES ALZ-NET: A LONG-TERM DATA COLLECTION AND SHARING NETWORK FOR NEW TREATMENTS

Retrieved on: 
Monday, August 1, 2022
Association, AAIC, HIV/AIDS, Dementia, Diagnosis, Time, Knowledge, Treatment, University, Multiple sclerosis, Education, American College, Neuroradiology, Sudarshan K. Aggarwal, Network, Health, SAN, Neuroscience, Research, Drug discovery, Alzheimer's Association, PET, Critical Path Institute, Safety, Multimedia, Degenerative disease, Brown University School of Public Health, Cancer, Conference, University of California, San Francisco Fetal Treatment Center, Ageing, FDA, Disease, Caregiver, Medical director, Patient, Department, Therapy, Neurology, ARIA, IDEAS, Center, Medicare, Society, Public health, Centers for Medicare & Medicaid Services, Medical imaging, Pharmaceutical industry, Medicine, Residential care, Medicine, Alzheimer's disease, Biostatistics, Memory

ALZ-NET is the first network developed specifically for new FDA-approved Alzheimer's treatments, collecting real-world evidence on drug effectiveness and side effects over a long period of time.

Key Points: 
  • ALZ-NET is the first network developed specifically for new FDA-approved Alzheimer's treatments, collecting real-world evidence on drug effectiveness and side effects over a long period of time.
  • The announcement was made today at the Alzheimer's Association International Conference (AAIC ) 2022 in San Diego and virtually.
  • "In collaboration with partners and scientific leaders, we are looking to develop the future of Alzheimer's and dementia treatment and diagnostics."
  • "The Alzheimer's Association and its partners are working tirelessly to ensure access, safety and efficacy of treatments for patients," Carrillo said.

Tevogen Bio Announces Positive Safety Results Upon Completion of Patient Enrollment in Proof-of-Concept Clinical Trial of T cell Therapy for Elderly or High-Risk COVID-19 Patients

Retrieved on: 
Monday, August 1, 2022
Biotechnology, Health, Consumer, Other Health, Pharmaceutical, Stem Cells, Research, Infectious Diseases, Hospitals, Genetics, Science, COVID-19, Seniors, Clinical Trials, Virus, Patient, Diabetes, Severe acute respiratory syndrome coronavirus 2, COVID-19, Kidney, Omicron, Cytokine release syndrome, Genome, Degenerative disease, Forward-looking statement, Research, Risk, CRS, Toxic shock syndrome, Safety, Cancer, Lung, Virology, Cell, Clinical trial, Liver, Review, Company, Heart, Malignancy, Hypertension, Neurology, Bio, DNP, Terminology, CTL, Thomas Jefferson University Hospital, Obesity, Medicine, Pharmaceutical industry, Vaccine, Delta

Patients received one of four escalating dose levels, with enrollment completed for all levels in nine months.

Key Points: 
  • Patients received one of four escalating dose levels, with enrollment completed for all levels in nine months.
  • Patients treated earlier in the trial were infected with the Delta variant of COVID-19, with subsequent patients having Omicron and its subvariants of COVID-19.
  • No dose-limiting toxicities or significant treatment-related adverse events, including Cytokine Release Syndrome (CRS), were observed for any patient at any dose level.
  • Tevogen Bio is driven by a team of distinguished scientists and highly experienced biopharmaceutical leaders who have successfully developed and commercialized multiple franchises.

Single-Cell Bioinformatics Software and Services Market worth $504.8 Million by 2030 - Exclusive Report by InsightAce Analytic

Retrieved on: 
Monday, August 1, 2022
Proteomics, SomaLogic, Investment, QIAGEN, NanoString Technologies, Genome, Industry, Research, Oncology, Abraxis BioScience, Academic institution, Drug discovery, Partnership, NIPD, Software, Ultra, BioLinux, BGI, Transcriptome, US, Data analysis, Isoplexis, Gene, CAGR, Cell, Adoption, Uniloc USA, Inc. v. Microsoft Corp., Illumina, Inc., Single-cell analysis, Neurology, IOT, Microbiology, BioBam Bioinformatics, BD, Services marketing, Renewable energy, Fine chemical, Mobile phone, Immunology, Application, Illumina

Ltd. announces the release of a market assessment report on the " Global Single-Cell Bioinformatics Software and Services Market By Product (Bioinformatics Software and Bioinformatics Services), Application (Oncology, Immunology, Neurology, Non-invasive Prenatal Diagnosis (NIPD), Microbiology, and Other Applications), End-user (Research and Academic Institutes, Biopharmaceutical Companies, and Others) Trends, Industry Competition Analysis, Revenue and Forecast To 2030."

Key Points: 
  • Ltd. announces the release of a market assessment report on the " Global Single-Cell Bioinformatics Software and Services Market By Product (Bioinformatics Software and Bioinformatics Services), Application (Oncology, Immunology, Neurology, Non-invasive Prenatal Diagnosis (NIPD), Microbiology, and Other Applications), End-user (Research and Academic Institutes, Biopharmaceutical Companies, and Others) Trends, Industry Competition Analysis, Revenue and Forecast To 2030."
  • According to the latest research by InsightAce Analytic, the global single-cell bioinformatics software and services market is valued at US$ 235.3 million in 2021, and it is expected to reach US$ 504.8 million by 2030, with a CAGR of 9.17% during the forecast period of 2022-2030.
  • High capital requirements, lack of expertise and infrastructure and analytical challenges in metabolite analysis will hamper the single-cell bioinformatics software and services market.
  • @ https://www.insightaceanalytic.com/enquiry-before-buying/1347
    Global Single-Cell Bioinformatics Software and Services Market, by Product, 2022-2030 (Value US$ Mn)
    Global Single-Cell Bioinformatics Software and Services Market, by Application, 2022-2030 (Value US$ Mn)

Single-Cell Bioinformatics Software and Services Market worth $504.8 Million by 2030 - Exclusive Report by InsightAce Analytic

Retrieved on: 
Monday, August 1, 2022
Proteomics, SomaLogic, Investment, QIAGEN, NanoString Technologies, Genome, Industry, Research, Oncology, Abraxis BioScience, Academic institution, Drug discovery, Partnership, NIPD, Software, Ultra, BioLinux, BGI, Transcriptome, US, Data analysis, Isoplexis, Gene, CAGR, Cell, Adoption, Uniloc USA, Inc. v. Microsoft Corp., Illumina, Inc., Single-cell analysis, Neurology, IOT, Microbiology, BioBam Bioinformatics, BD, Services marketing, Renewable energy, Fine chemical, Mobile phone, Immunology, Application, Illumina

Ltd. announces the release of a market assessment report on the " Global Single-Cell Bioinformatics Software and Services Market By Product (Bioinformatics Software and Bioinformatics Services), Application (Oncology, Immunology, Neurology, Non-invasive Prenatal Diagnosis (NIPD), Microbiology, and Other Applications), End-user (Research and Academic Institutes, Biopharmaceutical Companies, and Others) Trends, Industry Competition Analysis, Revenue and Forecast To 2030."

Key Points: 
  • Ltd. announces the release of a market assessment report on the " Global Single-Cell Bioinformatics Software and Services Market By Product (Bioinformatics Software and Bioinformatics Services), Application (Oncology, Immunology, Neurology, Non-invasive Prenatal Diagnosis (NIPD), Microbiology, and Other Applications), End-user (Research and Academic Institutes, Biopharmaceutical Companies, and Others) Trends, Industry Competition Analysis, Revenue and Forecast To 2030."
  • According to the latest research by InsightAce Analytic, the global single-cell bioinformatics software and services market is valued at US$ 235.3 million in 2021, and it is expected to reach US$ 504.8 million by 2030, with a CAGR of 9.17% during the forecast period of 2022-2030.
  • High capital requirements, lack of expertise and infrastructure and analytical challenges in metabolite analysis will hamper the single-cell bioinformatics software and services market.
  • @ https://www.insightaceanalytic.com/enquiry-before-buying/1347
    Global Single-Cell Bioinformatics Software and Services Market, by Product, 2022-2030 (Value US$ Mn)
    Global Single-Cell Bioinformatics Software and Services Market, by Application, 2022-2030 (Value US$ Mn)

BrainCheck Launches Investigator Initiated Research (IIR) Grant Program For Brain and Cognitive Disorders Research

Retrieved on: 
Monday, August 1, 2022
Biotechnology, General Health, Neurology, Mental Health, Health, Aurora, AAIC, Dementia, Diagnosis, UPMC, IIR, Cleveland Clinic, Physician, Traumatic brain injury, Twitter, Booth, CEO, Research, Alzheimer's disease, Conference, HIV disease progression rates, Advocate Aurora Health, Technology, Â, Patient, Stroke, Faculty, CPT, Population, Pharmaceutical industry, Medicine

BrainCheck Inc. , developer of an innovative digital cognitive assessment and care platform, today announced an Investigator Initiated Research (IIR) Grant Program to help fund research for evaluation, diagnosis, treatment and care for brain related disease.

Key Points: 
  • BrainCheck Inc. , developer of an innovative digital cognitive assessment and care platform, today announced an Investigator Initiated Research (IIR) Grant Program to help fund research for evaluation, diagnosis, treatment and care for brain related disease.
  • Awardees will be provided one-year research funding and free access to the BrainCheck platform.
  • BrainChecks Investigator Initiated Research Grant Program assists researchers developing innovative and much-needed treatments for these conditions, said Yael Katz, co-founder and CEO of BrainCheck.
  • BrainCheck provides rapid, mobile cognitive assessment and decision support technology to physicians, empowering them to deliver high-quality, personalized cognitive health care to patients everywhere.